Key Documents

View All Documentation

V9889

Valacyclovir hydrochloride hydrate

Name: Valacyclovir hydrochloride hydrate
Brand: SIGMA

≥98% (HPLC), solid

Synonym(s):

2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester monohydrochloride, L-Valine, Valtrex

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₃H₂₀N₆O₄· HCl · xH₂O

CAS Number:

124832-27-5

Molecular Weight:

360.80 (anhydrous basis)

UNSPSC Code:

12352200

PubChem Substance ID:

329830241

NACRES:

NA.32

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white

solubility

H₂O: >20 mg/mL

antibiotic activity spectrum

viruses

mode of action

DNA synthesis | interferes

storage temp.

room temp

SMILES string

O.Cl.CC(C)[C@H](N)C(=O)OCCOCn1cnc2C(=O)NC(N)=Nc12

InChI

1S/C13H20N6O4.ClH.H2O/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20;;/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20);1H;1H2/t8-;;/m0../s1

InChI key

KNOVZDRKHSHEQN-JZGIKJSDSA-N

Biochem/physiol Actions

Valacyclovir hydrochloride hydrate is a potent inhibitor of viral DNA polymerase.

Valacyclovir hydrochloride hydrate is potent inhibitor of viral DNA polymerase. It is a prodrug of acyclovir that is useful in viral, AIDS, and immune system regulation research.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection.

Mark Beswick et al.

Journal of virology, 87(2), 779-789 (2012-11-02)

Cytomegalovirus (CMV) infection leads to the development of adaptive and humoral immune responses that are among the largest for any pathogen, and intriguingly, the magnitude of the immune response increases with age, a phenomenon termed "memory inflation." Elevated CMV-specific immunity

Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.

Toshihiro Fukushima et al.

Anticancer research, 32(12), 5437-5440 (2012-12-12)

In patients with multiple myeloma (MM), bortezomib is associated with a significant risk of Varicella zoster virus (VZV) reactivation. There are some reports that acyclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be reduced by

Impact of Fractional Ablative Carbon Dioxide Laser on the Treatment of Rhinophyma.

Maine Trece de Siqueira Santos do Amaral et al.

Aesthetic surgery journal, 39(4), NP68-NP75 (2018-09-12)

Rhinophyma results in nasal deformity, which may lead to significant distress, embarrassment, social isolation, and low self-esteem. Fractional carbon dioxide (CO2) laser treatment is a simple, noninvasive, outpatient procedure with a low complication rate that has proved useful in rhinophyma

The spectrum of vaccine therapies for patients with glioblastoma multiforme.

Laura K Aguilar et al.

Current treatment options in oncology, 13(4), 437-450 (2012-08-21)

Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the central nervous system (CNS) and one of the most lethal cancers in adults and children. Despite aggressive treatment with surgery, radiation, and chemotherapy, median survival is less than

Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Adnan H Siddiqui et al.

Neurology, 83(5), 441-449 (2014-07-01)

We report the results of the investigation of safety and efficacy of venous angioplasty in patients with multiple sclerosis (MS) with findings of extracranial venous anomalies, considered hallmarks of chronic cerebrospinal venous insufficiency (CCSVI), in a 2-phase study (ClinicalTrials.gov NCT01450072).

View All Related Papers

Global Trade Item Number

SKU	GTIN
V9889-250MG	04061833077832
V9889-50MG	04061833077849

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service